Dr. Yachana Mishra is working as an Associate Professor at the School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India. She received her Ph.D. degree from Indian Grassland and Fodder Research Institute (IGFRI), Bundelkhand University, Jhansi (U.P.), India. She has published 50 research and review articles, 25 International book chapters, 5 International books, 2 Indian patents (Filed) and 3 Indian Copyrights (Granted). Dr. Mishra has 15+ years of academic and research experience. She is a life member of different reputed organizations like Indian Science Congress Association, Kolkata (India), and the Society of Pharmaceutical Education and Research (SPER), India. Her research areas include nanomedicine, cancer, diabetes, phytopharmaceuticals, and nanocarriers.
100
Scopus Publications
Scopus Publications
From Etiology to Therapy: A Comprehensive Review of Pediatric Community-acquired Pneumonia Yachana Mishra Current Pediatric Reviews, 2026 Introduction: Community-acquired pneumonia (CAP) is a significant contributor to illness and hospitalization among children worldwide. Pediatric CAP continues to provide a challenge to clinicians, despite considerable progress in medical research and immunization initiatives, owing to its varied origin, symptomatology that overlaps with other respiratory illnesses, and evolving microbial patterns. This review aims to (1) consolidate existing knowledge on the etiology and pathogenesis of pediatric CAP, (2) critically assess the significance of emerging biomarkers and diagnostic instruments in clinical decision-making, and (3) delineate modern treatment strategies and preventive measures to enhance patient outcomes. Methods: From scientific articles published over the last 10 years in different scientific platforms, including PubMed, Scopus, Web of Science, and Google Scholar, potentially relevant literature was compiled to update on biomarkers and innovative diagnostic tools for pediatric CAP. Results: In pediatric CAP, microbial pathogenesis is a critical background metric. Eight biomarkers, including C-reactive protein (CRP), procalcitonin (PCT), the neutrophil-to-lymphocyte ratio (NLR), serum amyloid A (SAA), and S100 proteins, have been reviewed with new diagnostic algorithms and instruments to assess disease severity and prognosis. Discussion: To demonstrate the current status of pediatric CAP diagnosis and therapy, seventeen clinical studies have been included. By integrating clinical expertise and developing efficient treatment strategies, this study offers a comprehensive perspective on improving outcomes for children with CAP. Conclusion: Understanding the disease's context is crucial for treatment, research, and prevention. In addition to minimizing diagnostic ambiguity, antibiotic usage, antimicrobial resistance, and biomarker roles and clinical value in pediatric CAP must be addressed.
Global Surveillance and Early Warning Systems for Neglected Viruses Aman Shukla, Vijay Mishra, Alaa A. A. Aljabali, Yachana Mishra Neglected Viruses, 2026 Global public health is still seriously threatened by neglected viruses, which are especially dangerous in low- and middle-income nations with inadequate healthcare systems. This chapter examines the geographic distribution and epidemiological trends of these viruses, highlighting the critical need for early warning systems and thorough surveillance. It looks at how these systems have changed over time and how important they are for early epidemic identification, risk assessment, and containment. We go into great detail about fundamental elements like surveillance tactics, data gathering techniques, and analytical frameworks as well as new technical advancements like artificial intelligence, machine learning, and big data analytics that are revolutionising the way we track and anticipate viral threats. Important international networks that promote cooperative responses are also highlighted in the chapter, such as the World Health Organization's activities and several national programmes. There are still many obstacles to overcome in spite of these developments, especially in the areas of finance, logistics, and moral leadership. The chapter provides illustrative case studies to demonstrate effective surveillance strategies and their beneficial effects on public health outcomes and outbreak control. In order to improve the capacity for early detection, it highlights potential future paths including predictive modelling and the creation of next-generation diagnostic instruments. Through the integration of research, technology, and policy, this chapter emphasises how important it is to improve global readiness for overlooked viral dangers.
Lassa Virus: Hidden Threats and Unseen Dangers Vijay Mishra, Aminata Lowe, Alaa A. A. Aljabali, Yachana Mishra Neglected Viruses, 2026 Lassa virus (LASV), a member of the Arenaviridae family, is a zoonotic pathogen responsible for Lassa fever, a haemorrhagic disease endemic to West Africa. First identified in Nigeria in 1969, LASV has since been classified as an Old-World arenavirus with unique virological and epidemiological characteristics. The virus is maintained in rodent reservoirs, primarily Mastomys natalensis, and spreads to humans through direct contact with contaminated excreta or via human-to-human transmission. Endemic regions, including Nigeria, Sierra Leone, Guinea, and Liberia, report thousands of infections annually, with case fatality rates reaching up to 20% in severe cases. Survivors often suffer long-term complications such as hearing loss. The virology of LASV reveals a bisegmented RNA genome with ambisense coding, encoding essential viral proteins involved in replication, immune evasion, and pathogenicity. Its transmission cycle and replication mechanisms contribute to its high infectivity, particularly in healthcare settings. Diagnosis remains a challenge due to overlapping symptoms with other haemorrhagic fevers, but molecular methods such as reverse transcription polymerase chain reaction have improved detection. Despite advances in antiviral treatments like ribavirin, effective therapy remains limited. Vaccine development efforts are ongoing, with several candidates in clinical trials. Public health measures, including rodent control and community education, play a crucial role in prevention. Given the potential for regional and global spread, Lassa fever remains a significant public health threat. This chapter explores the latest advancements in LASV research, diagnosis, treatment, and prevention, highlighting critical gaps and future directions for improved disease control and eradication efforts.
AI-Driven Precision Medicine for Lysosomal Storage Diseases Alaa A. A. Aljabali, Mohammad Obeid, Omar Gammoh, Walhan Alshaer, Esam Qnais, Abdelrahim Alqudah, Vijay Mishra, Yachana Mishra, Mohamed El-Tanani Current Bioinformatics, 2026 Lysosomal Storage Diseases (LSDs) are a group of rare genetic disorders characterized by impaired lysosomal degradation leading to the accumulation of undegraded macromolecules due to defective lysosomal function. Despite advances, challenges include timely diagnosis, personalized intervention, and treatment optimization. Artificial Intelligence (AI) is becoming a transformative part of precision medicine by addressing limitations via new diagnostic and pharmacological tools. This review examines AI applications in LSD management, from diagnostic accuracy through imaging and multi-omics, to drug discovery optimization. A comprehensive literature search was conducted using databases such as PubMed, Scopus, Web of Science, and Google Scholar. The search combined controlled vocabulary and free-text terms (e.g., "lysosomal storage diseases," "artificial intelligence," "machine learning," and "drug discovery"). Studies published in English over the past 10 years were included based on relevance, clinical applicability, and methodological rigor. Studies without AI-LSD applications or experimental validation were excluded. AI demonstrates potential through explainable AI, federated learning, and digital twins. Integration with wearable sensors and gene editing tools shows promise for monitoring and treatment prediction in LSD care. However, considerable barriers exist regarding data standardization, algorithmic bias, and ethical concerns. While AI has demonstrated potential in enhancing diagnostic accuracy, integrating multi-omics data, and optimizing drug discovery, challenges such as data standardization, algorithmic bias, and regulatory compliance must be addressed for broader clinical adoption. Future efforts require interdisciplinary collaboration, robust research frameworks, and regulatory policies to facilitate ethical and effective AI-driven precision medicine solutions in LSD treatment.
Navigating Zoonotic Landscapes: From Genomic Insights to Ethical Frontiers Alaa A. A. Aljabali, Abdelrahim Alqudah, Rasha M. Bashatwah, Rawan Alsharedeh, Esam Qnais, Omar Gammoh, Vijay Mishra, Yachana Mishra, Mohamed El-Tanani, Taher Hatahet Zoonotic Diseases, 2025 Viral zoonoses represent a critical intersection of global health, ecology, and ethical issues. Pathogens that pass from animals to humans. This review examines the complex landscape of viral zoonoses, including their mechanisms, impact, and mitigation strategies. We begin with insights into the historical context and significance of these diseases and then explore spillover mechanisms influenced by genetic, ecological, and anthropogenic factors. This review covers the host range, transmission dynamics, and immunological barriers, including viral detection, adaptation, and immune evasion. Genomic insights have revealed the genetic determinants of host switching and adaptation, illuminating the dynamics of viral spillover events. We emphasize the anticipation and prevention of zoonotic events, highlighting surveillance, early warning systems, and the “One Health” approach. Using case studies of outbreaks such as Ebola, avian influenza, and COVID-19, this review examines the real-world consequences of zoonotic diseases. We then discuss interventions, including mitigation strategies and vaccination, and their ethical and social implications. Drawing on past outbreaks, we provide recommendations for the future, aiming to balance human health, conservation, and animal welfare. This review aims to inform professionals, academics, and policymakers by offering a multidisciplinary perspective on the complex world of viral zoonoses and strategies to protect global health.
DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR THE DETERMINATION OF RESVERATROL IN BULK DOSAGE FORM, COMMERCIAL TABLET, AND MULTIWALLED CARBON NANOTUBES-BASED FORMULATION NEHA SHARMA, YACHANA MISHRA, NEELAM SHARMA, VIJAY MISHRA International Journal of Applied Pharmaceutics, 2025 Objective: Resveratrol (RES), a polyphenol, is a promising option to treat multiple diseases due to its anticancer, cardioprotective, anti-inflammatory, and antioxidant activities. The present study was designed to develop and validate a simple, precise, rapid and reproducible analytical method for the detection of RES in different formulations. Methods: A novel analytical technique was developed and validated for the detection of RES via ultrafast liquid chromatography utilizing C18 column. Methanol along with high-performance liquid chromatography (HPLC) grade water (40:60) was used as a mobile phase with a rate of flow of 0.8 ml/min. This technique has been validated following the International Conference for Harmonization (ICH) Q2 (R1) guidelines. The method's accuracy was determined through the percent recovery within the limit of 95 to 105%. Results: The method demonstrated linearity within the 2-10 µg/ml range, exhibiting a regression coefficient of 0.997. The precision of the method was indicated by the percentage RSD, which was recorded to be less than 2%. Limit of detection (LOD), and limit of quantification (LOQ) were found to be 1.6 µg/ml and 4.8 µg/ml, respectively. The proposed approach has been proved to be robust because the response did not significantly change due to a change in the rate of flow, along with the composition of the mobile phase. Conclusion: The results of the study demonstrated that the developed method has passed all the validation test parameters and can be applied for the estimation of RES in bulk dosage form, commercial tablet, and developed multiwalled carbon nanotube (MWCNTs)-based formulations.
Bioanalytical method development of nevirapine, fosamprenavir calcium and its metabolite amprenavir by RP-HPLC in rat plasma Neha Srivastava, Vijay Mishra, Bimlesh Kumar, Yachana Mishra, Vasanth Raj Palanimuthu Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 2025 The current analytical work focuses on the development of a bioanalytical method for anti-HIV drugs, nevirapine, fosamprenavir calcium, and its metabolite amprenavir. Fosamprenavir is a prodrug of amprenavir, digested by cellular phosphatases in vivo . Rat plasma was isolated from the collected rat blood by centrifugation and used for preparing stock solutions. A reverse-phase column (ODS C-18) was used for the development of the method and validation. The bioanalytical method was developed using the isocratic mode. The solvent system used is Methanol: Water: ACN (800 mL: 200 mL: 50 mL). The method was run at a flow rate of 0.5 mL/min, and 258 nm was the detection wavelength. The developed method showed retention at 8.705 min for nevirapine, 11.923 min for fosamprenavir calcium, and 14.391 min for amprenavir. The calibration curve was linear with a correlation coefficient (r 2 ) of 0.9916 for nevirapine, 0.9909 for fosamprenavir calcium, and 0.9879 min for amprenavir. The RSD of the accuracy, precision, and stability study of the method was found to be less than 2 % and was found to be acceptable. The method is reliable and does not show any kind of interference due to the plasma sample. Thus, the results support that a reliable, reproducible, and efficient method was developed, and validation was carried out for the estimation of the drug nevirapine, fosamprenavir, and its metabolite amprenavir in rat plasma samples. • HPLC method development and validated for anti-HIV drugs in rat plasma. • A simultaneous method of nevirapine, fosamprenavir, and its metabolite amprenavir was developed. • The method was validated using ICH guidelines and found to be reliable, repeatable, and showed high precision.
Phytochemicals in Cancer Therapy: A Structured Review of Mechanisms, Challenges, and Progress in Personalized Treatment Alaa A. A. Aljabali, Mohammad A. Obeid, Rasha M. Bashatwah, Esam Qnais, Omar Gammoh, Abdelrahim Alqudah, Vijay Mishra, Yachana Mishra, Mohammad Ahmed Khan, Suhel Parvez, Mohamed El‐Tanani, Taher Hatahet Chemistry and Biodiversity, 2025 Cancer is a major global health concern. Therefore, new treatment options are needed. The phytochemicals have different chemical structures. It also exhibits several other biological activities. Therefore, these compounds are promising anticancer agents. This review aims to identify and assess new candidates for anticancer therapy. Researchers have identified these compounds among the well‐studied plant chemicals and their actions. Thus, these compounds can be used in anticancer therapies. The popularity of phytochemicals has grown. Currently, these are the subjects of extensive investigational studies. However, obstacles remain in its development and translation for clinical use. This is especially true for low bioavailability. These compounds also exhibit a wide range of activities, toxicities, and regulatory activities. These are necessary for the isolation and characterization of phytochemicals. This review discusses these challenges and the recent progress. Emphasis has been placed on integrating traditional knowledge of medicines with current biomedical advancements to augment the efficacy of phytoconstituents for cancer treatment. The review indicates new treatment frameworks with the synergy of traditional systems of medicine (e.g., Traditional Chinese Medicine [TCM] and Ayurveda) and new approaches today, such as nanotechnology and artificial intelligence‐assisted drug discovery. This review also highlights the clinical efficacy of such phytoconstituents and addresses key developmental bottlenecks, such as bioavailability, regulatory barriers, and standardized methods of extraction. These include the extraction methods, delivery systems, and clinical findings. It focuses on the merging of modern and traditional medicine. The goal of this study was to maximize the potential of these phytochemicals. This will help to create successful cancer treatments. A thorough analysis was done using primary databases, namely PubMed, Scopus, Web of Science, and Google Scholar, for articles between 2020 and 2023. The relevant literature was searched using keywords such as phytochemicals, anticancer mechanisms, bioavailability, delivery systems, and clinical efficacy. The selected articles included peer‐reviewed studies that compared the anticancer mechanisms of phytochemicals, challenges encountered in their development, new advances in extraction and delivery technologies, and clinical reports of their therapeutic efficacy. This approach allowed a wide synthesis of existing knowledge around phytochemicals as anticancer drugs. This review summarizes our knowledge of phytochemicals as potential anticancer agents. This finding fills a gap in the literature. This offers new insights into their roles in personalized cancer treatment. This explains the mechanisms of action and challenges in development. This places these compounds at the forefront of, and complements, cancer treatment. Considerable research is required to boost personalized oncology research. This leads to improved patient outcomes.
Nanomedicine research, development, and current clinical status Molakpogu Ravindra Babu, Shaik Abdul Rahaman, Garla Venkateswarlu, Yachana Mishra, Vijay Mishra Intelligent Nanobiosystems in Medicine and Healthcare Volume 1 Fundamentals Fabrication and Commercialization, 2025
Microfluidics platforms of nanobiosystems: Fabrication aspects Yachana Mishra, Ashi Varshney, Alaa A.A. Aljabali, Vladimir N. Uversky, Murtaza M. Tambuwala, Vijay Mishra Intelligent Nanobiosystems in Medicine and Healthcare Volume 1 Fundamentals Fabrication and Commercialization, 2025
Modern industrial perspective of nanobiosystems Molakpogu Ravindra Babu, Yachana Mishra, Shaik Abdul Rahaman, Prathap Madeswara Guptha, Garla Venkateswarlu, Manoj Gadewar, Suddikattu Bhargavi Intelligent Nanobiosystems in Medicine and Healthcare Volume 1 Fundamentals Fabrication and Commercialization, 2025
Intelligent nanobiosystems in tissue engineering A.G. Hariharan, L.S. Sathyapriya, Revathi A. Gupta, R. Narayana Charyulu, Kalvatala Sudhakar, Yachana Mishra, Vijay Mishra Intelligent Nanobiosystems in Medicine and Healthcare Volume 2 Applications of Intelligent Nanobiosystems, 2025
Self-nanoemulsifying drug delivery systems in targeted delivery of bioactives Kalvatala Sudhakar, Aditya Narayan Singh, Shruti Sharma, Sunil Yadav, Aditya Halwa, Sanjay Jain, R. Narayana Charyulu, Yachana Mishra Intelligent Nanobiosystems in Medicine and Healthcare Volume 2 Applications of Intelligent Nanobiosystems, 2025
Cancer Immunotherapies: Navigating the Immune Landscape Rakesh Kumar, Joseph Finian Maleme, Shubham Kumar, Kalvatala Sudhakar, Darshan R. Telange, Oshin Maiti, Pratibha Sahoo, Alaa A.A Aljabali, Vijay Mishra, Yachana Mishra Current Cancer Drug Targets, 2025
Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions Alaa A. A. Aljabali, Mohammad A. Obeid, Omar Gammoh, Mohamed El-Tanani, Vijay Mishra, Yachana Mishra, Sumedha Kapre, Sushesh Srivatsa Palakurthi, Sk. Sarif Hassan, Debaleena Nawn, Kenneth Lundstrom, Altijana Hromić-Jahjefendić, Ángel Serrano-Aroca, Elrashdy M. Redwan, Vladimir N. Uversky, Murtaza M. Tambuwala Cancers, 2024
Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives Seyed Hossein Shahcheraghi, Maliheh Alimardani, Malihe Lotfi, Marzieh Lotfi, Vladimir N. Uversky, Stephanie Tamdem Guetchueng, Sushesh Srivatsa Palakurthi, Nitin B. Charbe, Altijana Hromić-Jahjefendić, Alaa A.A. Aljabali, Manoj M. Gadewar, Sumira Malik, Rohit Goyal, Mohamed El-Tanani, Vijay Mishra, Yachana Mishra, Murtaza M. Tambuwala Pathology Research and Practice, 2024
The role of the gut microbiome in gastrointestinal cancers Yachana Mishra, Abhigyan Ranjan, Vijay Mishra, Aditi Chattaraj, Alaa A.A. Aljabali, Mohamed El-Tanani, Altijana Hromić-Jahjefendić, Vladimir N. Uversky, Murtaza M. Tambuwala Cellular Signalling, 2024
Overview of carbon nanotubes as drug delivery system Sujit Bose, Yachana Mishra, A.A.A. Aljabali, Murtaza M. Tambuwala, Vijay Mishra Progress and Prospect of Nanocarriers Design Concept and Recent Advances, 2024
Diabetes mellitus in pregnancy Management of Diabetes Mellitus Based on Natural Products, 2023
Natural products in the treatment of diabetes: An insight into the mechanism of action Management of Diabetes Mellitus Based on Natural Products, 2023
A targeted therapeutic approach based on medicinal plants in the management of diabetes mellitus Management of Diabetes Mellitus Based on Natural Products, 2023
Sodium-glucose co-transporter 2 inhibitors in diabetes Management of Diabetes Mellitus Based on Natural Products, 2023
The pathophysiology of diabetes mellitus Management of Diabetes Mellitus Based on Natural Products, 2023
The social determinants of diabetes Management of Diabetes Mellitus Based on Natural Products, 2023
Impact of exosome therapy on pancreatic cancer and its progression Mohamed El-Tanani, Hamdi Nsairat, Ismail I. Matalka, Alaa A. A. Aljabali, Vijay Mishra, Yachana Mishra, Gowhar A. Naikoo, Sai Raghuveer Chava, Nitin B. Charbe, Murtaza M. Tambuwala Medical Oncology, 2023
Nanomaterials and Their Impact on the Immune System Alaa A. Aljabali, Mohammad A. Obeid, Rasha M. Bashatwah, Ángel Serrano-Aroca, Vijay Mishra, Yachana Mishra, Mohamed El-Tanani, Altijana Hromić-Jahjefendić, Deepak N. Kapoor, Rohit Goyal, Gowhar A. Naikoo, Murtaza M. Tambuwala International Journal of Molecular Sciences, 2023
Applications of trimetallic nanomaterials as Non-Enzymatic glucose sensors Israr U. Hassan, Gowhar A. Naikoo, Fareeha Arshad, Fatima Ba Omar, Alaa A. A. Aljabali, Vijay Mishra, Yachana Mishra, Mohamed EL-Tanani, Nitin B. Charbe, Sai Raghuveer Chava, Ángel Serrano-Aroca, Murtaza M. Tambuwala Drug Development and Industrial Pharmacy, 2023
Cellular and molecular basis of therapeutic approaches to breast cancer Mohamed El-Tanani, Arwa Omar Al Khatib, Belal O. Al-Najjar, Ashok K. Shakya, Yahia El-Tanani, Yin-Fai Lee, Ángel Serrano-Aroca, Vijay Mishra, Yachana Mishra, Alaa A. Aljabali, Rohit Goyal, Poonam Negi, Marzieh Ramezani Farani, Maryam Moradi Binabaj, Amir Gholami, Nitin B. Charbe, Murtaza M. Tambuwala Cellular Signalling, 2023
Gene Therapy for Neuropsychiatric Disorders: Potential Targets and Tools Marzieh Lotfi, Murtaza M. Tambuwala, Seyed H. Shahcheraghi, Jamshid Ayatollahi, Alaa A.A. Aljabali, Mazhar S. Al-Zoubi, Pritam K. Panda, Vijay Mishra, Saurabh Satija, Nitin B. Charbe, Ángel Serrano-Aroca, Bojlul Bahar, Kazuo Takayama, Rohit Goyal, Amit Bhatia, Abdulmajeed G. Almutary, Abdullah M. Alnuqaydan, Yachana Mishra, Poonam Negi, Aaron Courtney, Paul A. McCarron, Hamid A. Bakshi CNS and Neurological Disorders Drug Targets, 2023
Advances in nanomaterial-based immunosensors for prostate cancer screening Rabia Khan, Fareeha Arshad, Israr U. Hassan, Gowhar A. Naikoo, Mona Z. Pedram, Mohammed Saeedi Zedegan, Hamed Pourfarzad, Alaa A.A. Aljabali, Ángel Serrano-Aroca, Yusuf Haggag, Vijay Mishra, Yachana Mishra, Martin Birkett, Murtaza M. Tambuwala Biomedicine and Pharmacotherapy, 2022
Recent advancement and biomedical applications of fungal metabolites Charanjit Kaur, Yachana Mishra, Vijay Mishra, Gaurav K. Saraogi, Murtaza M. Tambuwala New and Future Developments in Microbial Biotechnology and Bioengineering Recent Advances in Application of Fungi and Fungal Metabolites Current Aspects, 2020
